Sarepta therapeutics submits biologics license application for srp-9001 for the treatment of ambulant patients with duchenne muscular dystrophy

Cambridge, mass., sept. 29, 2022 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced that it has submitted a biologics license application (bla) to the u.s. food and drug administration (fda) for the accelerated approval of srp-9001 (delandistrogene moxeparvovec) to treat ambulant patients with duchenne muscular dystrophy. srp-9001 is an investigational gene therapy for duchenne being developed in partnership with roche.
SRPT Ratings Summary
SRPT Quant Ranking